Reinterpreting the matched-sibling relapse penalty in ATG-based allogeneic transplantation for myelodysplastic neoplasms: a question of dose, not donor

Naif I AlJohani · 2026

Read Reinterpreting the matched-sibling relapse penalty in ATG-based allogeneic transplantation for myelodysplastic neoplasms: a question of dose, not donor by Naif I AlJohani (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13421350.txt.

Description

AlJohani wrote a letter in 2026 disputing a study that questioned sibling donors in stem cell transplants for myelodysplastic neoplasms. The original Korean study of 391 patients found far higher five-year relapse with matched sibling donors than with unrelated or half-matched donors. Its authors suggested siblings may no longer be the best donor choice under the anti-rejection drug regimen used.

AlJohani argues the comparison is confounded by drug dose, not donor type. Over six in ten sibling recipients got a high dose of antithymocyte globulin, while no half-matched recipient did. Cited evidence shows high doses in sibling transplants raise relapse without cutting graft-versus-host disease, where donor cells attack the patient. The pattern of relapse and side effects fits total immune suppression better than donor source.

Catalog record

CREATORNaif I AlJohani
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE10 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13421350

Browse the full library · About the Tower of Babel